BackGenocea Biosciences Overview

Genocea Biosciences Long Term Debt

Genocea Biosciences's long-term debt is $8.4M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$8.37M
45.94% YoYΔ $-7.12M vs prior year quarter

Peer trimmed avg / median

Loading

Genocea Biosciences Long Term Debt History

Loading

Genocea Biosciences vs. peers: Long Term Debt Comparison

Loading

Genocea Biosciences Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Genocea Biosciences (GNCA) FAQ

As of the most recent data (March 2022), GNCA shows a long-term debt of $8.4M. That compares with $15M in the prior-year period — down 45.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GNCA's long-term debt is now $8.4M (was $15M) — a 45.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genocea Biosciences is outperforming or lagging.

Tracking GNCA's long-term debt over time shows whether Genocea Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $8.4M That compares with $15M in the prior-year period — down 45.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Genocea Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $8.4M) with ownership activity and broader fundamentals.

Genocea Biosciences's long-term debt is $8.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.